Over glasses of Chablis at Fleming by Le Bilboquet in Manhattan, two longtime friends and biotech lifers hashed out the deal that will bring their wending and colorful careers back together after three decades.
Jeremy Levin, the professorial executive who has become one of the industry’s loudest voices on matters of social justice, is getting back into business with Sam Waksal, a hit-making drug developer with a gift for eloquence and a biography that doubles as biotech’s great unproduced screenplay.
“We’ve got a collaboration that was made in heaven,” Waksal said, grinning, in an interview.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect